SCHEMBL8286241

SCHEMBL8286241

CNc1nc2ccc(CCl)cc2n1Cc1nc(C)ccc1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 8/20 0.37
ALDH1A1 P00352 7/20 0.37
GFER P55789 1/20 0.37
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NOD1 Q9Y239 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HPGD P15428 4/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
RAB9A P51151 1/20 0.34
NOD2 Q9HC29 1/20 0.34
SOS1 Q07889 2/20 0.34
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2543033 0.99 KDM4E (0.39) MEN1KMT2AHTTKDM4EALDH1A1
SCHEMBL8286240 0.90 KDM4E (0.43) MEN1KMT2AHTTKDM4EALDH1A1
SCHEMBL8241914 0.84 SOS1 (0.43) KMT2AHTTKDM4EALDH1A1GFER
SCHEMBL8292644 0.83 KCNH2 (0.45) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL8286242 0.81 KDM4E (0.43) MEN1KMT2AHTTKDM4EALDH1A1
SCHEMBL8250145 0.80 TRPC5 (0.54) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL8241916 0.79 TRPC5 (0.49) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL2541947 0.78 MEN1 (0.32) MEN1KMT2AHTTKDM4EALDH1A1
SCHEMBL8284404 0.78 TRPC5 (0.40) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL8242386 0.75 KDM4E (0.48) KDM4EALDH1A1GFERHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 MEN1 4025/4885KMT2A 108/4885HTT 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.